Skip to main content
Equibles
AHCO logo

AHCO · AdaptHealth Corp. · Metrics

Track AHCO — free

Use AHCO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AHCO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.17 +0.07 (+1.15%) At close · Oct 22
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$841.24M
Shares
136.34M
Volume · Oct 22 2.18M Avg daily vol (3M) 3.02M

AHCO metrics

99 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.17
Market cap
$841.24M

Price action

20 metrics
Price change (1W)
-3.4%
Price change (30D)
+6.9%
Price change (3M)
-41.1%
Price change (6M)
-51.5%
Price change (YTD)
-38.1%
Price change (1Y)
-34.6%
Trailing year
Price change (5Y)
-75.9%
52-week high
$13.38
52-week low
$5.22
Change from 52-week high
-53.9%
Change from 52-week low
+18.2%
Annualized volatility
62.4%
Annualized volatility (3M)
92.1%
Beta
0.0
RSI (14D)
54.0
Price vs SMA 50
+5.4%
Price vs SMA 200
-33.9%
Avg volume (3M)
3.02M
Relative volume
0.7
Average dollar volume
$18.54M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
136.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 128.8%
EV / EBITDA
9.0×
reciprocal yield 11.1%
EV / EBIT
—
P / sales
0.2×
reciprocal yield 400.6%
P / book
0.6
reciprocal yield 163.9%
FCF yield
11.6%
TTM · current market cap
Buyback yield
0.0%
P / FCF
8.6
reciprocal yield 11.6%
P / operating cash flow
1.4
reciprocal yield 69.3%
Earnings yield
-27.3%

Historical valuation

8 metrics
P / E historical average (3Y)
22.7×
reciprocal yield 4.4%
P / E historical average (5Y)
26.5×
reciprocal yield 3.8%
EV / revenue historical average (3Y)
1.0×
reciprocal yield 97.2%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 74.4%
EV / EBIT historical average (3Y)
21.8×
reciprocal yield 4.6%
EV / EBIT historical average (5Y)
22.5×
reciprocal yield 4.4%
EV / EBITDA historical average (3Y)
16.0×
reciprocal yield 6.3%
EV / EBITDA historical average (5Y)
13.9×
reciprocal yield 7.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
16.9%
Operating margin
-3.9%
Trailing 12 months
Net margin
-6.8%
Gross profit (TTM)
$568.68M
Operating profit (TTM)
−$130.30M
Net income (TTM)
−$229.36M
Trailing 12 months
Diluted EPS (TTM)
$-1.68
FCF margin
2.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$24.98
Gross profit per diluted share (TTM)
$4.22
Operating profit per diluted share (TTM)
$-0.98
EBITDA per diluted share (TTM)
$2.15
Net income per diluted share (TTM)
$-1.71
Operating cash flow per diluted share (TTM)
$4.32
Free cash flow per diluted share (TTM)
$0.73
Capital expenditures per diluted share (TTM)
$3.59
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.17
Book value per share
$11.21

Growth

11 metrics
Revenue growth YoY
+12.7%
Year over year
Net income growth YoY
-1,012.7%
Revenue (TTM)
$3.37B
Trailing 12 months
EPS growth YoY
-1,090.0%
Shares change YoY
-0.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+3.0%
Revenue CAGR (5Y)
+25.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+7.1%

Quality

14 metrics
Return on equity
-16.6%
Return on assets
-5.3%
Debt / equity
1.4
Current ratio
1.1
EBITDA (TTM)
$291.68M
Free cash flow (TTM)
$97.68M
Quick ratio
1.0
Interest coverage
—
Net debt / EBITDA
6.1
Return on invested capital
—
Trailing 12 months
Net cash
−$1.78B
Latest balance sheet
Cash & equivalents
$47.96M
Total assets
$4.34B
Total debt
$1.89B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$583.27M
Capital expenditures (TTM)
$485.59M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$22.54M
R&D / revenue
—
Stock compensation / revenue
0.7%

Ownership (13F)

9 metrics
13F filers
241
13F filer change QoQ
-1
Institutional ownership
104.8%
Conviction holders (share of 13F filers)
1.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.5%
Holder tenure
16.4
Price vs estimated holder cost
-16.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
23.8%

Short interest

3 metrics
Short interest
7.0%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
$275,930
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1725255 CUSIP 00653Q102 13F (30d) 34 filings 34 filers Visit website Investor relations